# 119-s-4332: Medication Competition Act

119-s-4332, Medication Competition Act, is a 119th Congress bill sponsored by Sen. Hassan, Margaret Wood [D-NH] (D-NH); status introduced; PRIA reads it as touching household money (as of 2026-05-14).

- Canonical: https://policyrisk.com/legislation/119-s-4332
- As of: 2026-05-14
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-4332
- Congress: 119
- Title: Medication Competition Act
- Status: introduced
- Introduced: 2026-04-16
- Sponsor: Sen. Hassan, Margaret Wood [D-NH] (D-NH)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-05-14

## Summary

**Publish exclusivity expiration dates for biological products.** This bill would require the Secretary of Health and Human Services to determine and publish applicable exclusivity periods under paragraphs (6) and (7) on the public lists for biological products. - Interchangeable biological products: For products licensed on or after enactment the Secretary must list any exclusivity period under paragraph (6) no later than 30 days after the earliest date an expiration can be known. For products licensed before enactment the Secretary must list any such exclusivity period no later than 30 days after the later of enactment or the earliest date an expiration can be known. - Reference biological products: For products licensed on or after enactment the Secretary must include the expiration date of any exclusivity under paragraph (7) within 30 days after licensure. For products licensed before enactment the Secretary must include that expiration date no later than 2 years after enactment.

## Cosponsors (1)

- Sen. Budd, Ted [R-NC] (R-NC), 2026-04-16T00:00:00.000Z

## Provisions PRIA read

- Publish biologic drug exclusivity dates: benefit, medium. If enacted, this bill would require the Secretary of Health and Human Services to publish when certain biologic drug exclusivity periods end. It would cover first-interchangeable product exclusivity (paragraph (6)) and reference-product exclusivity (paragraph (7)). For reference products licensed o…

## Related bills

- 119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026
- 119-s-3990: PrEP Access and Coverage Act of 2026
- 119-s-1782: Charlotte Woodward Organ Transplant Discrimination Prevention Act
- 119-s-1639: American Innovation and Jobs Act
- 119-s-1241: Sanctioning Russia Act of 2025
- 119-s-545: Combating Illicit Xylazine Act

## Sources
- [119-s-4332 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/4332)

## Related
- [119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026](https://policyrisk.com/legislation/119-s-3923)
- [119-s-3990: PrEP Access and Coverage Act of 2026](https://policyrisk.com/legislation/119-s-3990)
- [119-s-1782: Charlotte Woodward Organ Transplant Discrimination Prevention Act](https://policyrisk.com/legislation/119-s-1782)
- [119-s-1639: American Innovation and Jobs Act](https://policyrisk.com/legislation/119-s-1639)
- [119-s-1241: Sanctioning Russia Act of 2025](https://policyrisk.com/legislation/119-s-1241)
- [119-s-545: Combating Illicit Xylazine Act](https://policyrisk.com/legislation/119-s-545)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-4332 (as of 2026-05-14).